Animal studies [75,77,79,80] have revealed that elevated hepatic de novo lipogenesis contributes significantly to MASLD, and inhibition of ATP-citrate lyase (ACLY), a key enzyme in lipogenesis, has been shown to effectively control hepatic steatosis. This evidence concerns the gene ACLY and Hepatic steatosis.